Transforming growth factor β1 overexpression in the nigrostriatal system increases the dopaminergic deficit of MPTP mice

Molecular and Cellular Neuroscience

Volumn 23, Issue 4, 2003, Pages 614-625

  Sánchez Capelo, Amelia ^a,c   Colin, Philippe ^a   Guibert, Bernard ^b   Biguet, Nicole Faucon ^a   Mallet, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Dopaminergic system; Gene transfer; MPTP mouse model; Parkinson's disease; Recombinant adenovirus; TGF 1

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; ENKEPHALIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE OVEREXPRESSION; GENE TRANSFER; MALE; MATURATION; MESENCEPHALON; MOUSE; NERVE CELL INHIBITION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RISK FACTOR; VIRUS RECOMBINANT;

ADENOVIRIDAE; PARKINSONIA;

EID: 0041659303     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-7431(03)00081-2     Document Type: Article

References (66)

1. Abercrombie M. Estimation of nuclear population from microtome section. Anat. Rec. 94:1946;239-247.
2. Akli S., Catherine C., Vigne E., Stratford-Perricaudet L.D., Poenaru L., Perricaudet M., Kahn A., Peschanski M.R. Transfer of a foreign gene into the brain using adenovirus vectors. Nature Genet. 3:1993;224-228.
3. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., Le Meur M., Borrelli E. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature. 377:1995;424-428.
4. Bemelmans A.P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther. 10:1999;2987-2997.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington clinical, morphological and neurochemical correlations . J. Neurol. Sci. 2:1973;415-455.
6. Bezard E., Jaber M., Gonon F., Boireau A., Bloch B. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl, 1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12:2000;2892-2900.
7. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA. 94:1997;8818-8823.
8. Brown P.D., Wakefield L.M., Levinson A.D., Sporn M.B. Physicochemical activation of recombinant latent transforming growth factor-beta's 1,2 and 3. Growth Factors. 3:1990;35-43.
9. Brunner A.M., Marquardt H., Malacko A.R., Lioubin M.N., Purchio A.F. Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor β1 precursor. J. Biol. Chem. 264:1989;13660-13664.
10. Castel-Barthe M.N., Jazat-Poindessous F., Barnéoud P., Vigne E., Revah F., Mallet J., Lamour Y. Direct intracerebral nerve growth factor gene transfer using a recombinant adenovirus effect on basal forebrain cholinergic neurons during aging . Neurobiol. Dis. 3:1996;76-86.
11. Cheramy A., Leviel V., Daudet F., Guibert B., Chesselet M.F., Glowinski J. Involvement of the thalamus in the reciprocal regulation of the two nigrostriatal dopaminergic pathways. Neuroscience. 6:1981;2657-2668.
12. Cheramy T.D., Chesselet M.F., Romo R., Leviel V., Glowinski J. Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways. Neuroscience. 8:1983;767-780.
13. Chesselet M.F., Chéramy T.D., Reisine T.D., Lubetzki C., Desban M., Glowinski J. Local and distal effects induced by unilateral striatal application of opiates in the absence or in the presence of naloxone on the release of dopamine in both caudate nuclei and substantiae nigrae of the cat. Brain Res. 258:1983;229-242.
14. Commissiong J.W., Takeshima T., Johnston J., Shimoda K. Effects of TGFβs on dopaminergic neurons in culture. Neurochem. Int. 30:1997;393-399.
15. Corti O., Sánchez-Capelo A., Colin P., Hanoun N., Hamon M., Mallet J. Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 96:1999;12120-12125.
16. De Luca A., Weller M., Fontana A. TGF-β-induced apoptosis of cerebellar granule neurons is prevented by depolarization. J. Neurosci. 16:1996;4174-4185.
17. Dünker N., Schuster N., Krieglstein K. Transforming growth factor beta modulates programmed cell death in the retina of the developing chick embryo. Development. 128:2001;1933-1942.
18. Erausquin G.A., Costa E., Hanbaner I. Calcium homeostasis, free radical formation, and trophic factor dependence mechanisms in Parkinson's disease. Pharmacol. Rev. 46:1994;467-481.
19. Flanders K.C., Lüdecke G., Engels S., Cissel D.S., Roberts A.B., Kondaiah P., Lafyatis R., Sporn M.B., Unsicker K. Localization and actions of Transforming growth factors-βs in the embryonic nervous system. Development. 113:1991;183-191.
20. Forno L.S. The Lewy body in Parkinson's disease. Yahr M.D., Bergmann K.J. Parkinson's Disease. Advances in Neurology. Vol. 45:1986;35-43 Raven Press, New York.
21. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
22. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration. 5:1996;299-312.
23. Goetz C.G., Jankovic J., Paulson G.W. Update on Parkinson's disease. Patient Care. 23:1989;124-162.
24. Irwin I., DeLanney L.E., Langston J.W. MPTP and ageing. Studies in the C57BL/6 mouse. Narabayashi H., Nagatsu T., Yanagisawa N., Mizumo Y. Advances in Neurology. Vol. 60:1993;197-206 Raven Press, New York.
25. Kane C.J., Brown G.J., Phelan K.D. Transforming growth factor-beta 2 both stimulates and inhibits neurogenesis of rat cerebellar granule cells in culture. Brain Res. Dev. Brain Res. 96:1996;46-51.
26. Knuckey N.M., Finch P., Palm D.E., Primiano M.J., Johanson C.E., Flanders K.C., Thompson N.L. Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following trasient forebrain ischemia. Mol. Brain Res. 40:1996;1-14.
27. Krieglstein K., Richter S., Farkas L., Schuster N., Dunker N., Oppenheim R.W., Unsicker K. Reduction of endogenous transforming growth factor beta prevents ontogenetic neuron death. Nature Neurosci. 3:2000;1085-1090.
28. + toxicity. EMBO J. 14:1995;736-742.
29. Krieglstein K., Unsicker K. Transforming growth factor β promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. Neuroscience. 63:1994;1189-1196.
30. Kurlan L.T., Kurtzke J.F., Goldberg I.D., Choi N.W., Williams G. Parkinsonism. Kurland L.T., Kurtzke J.F., Goldberg I.D. Epidemiology of Neurologic and Sense Organ Disorders. 1973;41-63 Harvard Univ. Press, Cambridge.
31. Le Gal La Salle G., Robert J.J., Berrard S., Ridoux V., Stratford-Perricaudet L.D., Perricaudet M., Mallet J. An adenovirus vector for gene transfer into neurons and glia in the brain. Science. 259:1993;988-990.
32. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Browstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
33. Leviel V., Gobert A., Guibert B. Direct observation of dopamine compartmentation in striatal nerve terminal by "in vivo" measurement of the specific activity of released dopamine. Brain Res. 499:1989;205-213.
34. Lindsay R.M., Altar C.A., Cedarbaum J.M., Hyman C., Wiegand S.J. The therapeutic potential of neurotophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124:1993;103-118.
35. Lowry O.H., Rosebrought N.J., Farr A.L., Randall R.J. Protein measurement with Folin reagent. J. Biol. Chem. 193:1951;265-275.
36. MacCarney-Francis N.L., Wahl S.M. Transforming growth factor β a matter of life and death . J. Leukocyte Biol. 55:1994;401-408.
37. Machida H., Ogawa K., Funaba M., Mizutani T., Tsujimoto M. mRNA expression of type I and type II receptors for activin, transforming growth factor-β, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl. Eur. J. Endocrinol. 143:2000;705-710.
38. Massague J. How cells read TGFβ signals. Nature Rev. Mol. Cell Biol. 1:2000;169-178.
39. Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H., Brownstein M.J. Alpha synuclein in neurodegenerative disorders murderer or accomplice? Nature Med. 4:1998;755-757.
40. Mogi M., Harada M., Kondo T., Narabayashi H., Rieder P., Nagatsu T. TGFβ1 levels are elevated in the striatum and the ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193:1995;129-132.
41. Nussbaum R.L. Putting the Parkin into Parkinson's. Nature. 392:1998;544-545.
42. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., Li L., Miyazono K., ten Dijke P., Kim S., Li E. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis. Proc. Natl. Acad. Sci. USA. 97:2000;2626-2631.
43. Peress N.S., Perillo E. Differential expression of TGFβ1, 2, and 3 isotypes in Alzheimer's disease a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains . J. Neuropathol. Exp. Neurol. 54:1995;802-811.
44. Poulsen K.T., Armanini M.P., Klein R.D., Hynes M.A., Phillips H.S., Rosenthal A. TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic neurons. Neuron. 13:1994;1245-1252.
45. Prehn J.H., Krieglstein J. Opposing effects of transforming growth factor-beta 1 on glutamate neurotoxicity. Neuroscience. 60:1994;7-10.
46. Prehn J.H., Miller R.J. Opposite effects of TGF-beta 1 on rapidly- and slowly-triggered excitotoxic injury. Neuropharmacology. 35:1996;249-256.
47. Ridoux V., Robert J.J., Zhang X., Perricaudet M., Mallet J., Le Gal La Salle G. Adenoviral vectors as functional retrograde neuronal tracers. Brain Res. 648:1994;171-175.
48. Sánchez-Capelo A., Corti O., Mallet J. Adenovirus-mediated overexpression of TGFβ1 in the striatum decreases dopaminergic cell survival in embryonic nigral grafts. NeuroReport. 10:1999;2169-2179.
49. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25:2000;302-305.
50. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain implications for Parkinson's disease . Science. 293:2001;263-269.
51. Schuster N., Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res. 307:2002;1-14.
52. Song D.D., Haber S.N. Striatal responses to partial dopaminergic lesion evidence for compensatory sprouting . J. Neurosci. 20:2000;5102-5114.
53. Sporn M.B., Roberts A.B. TGFβ Recent progress and new challenges . J. Cell Biol. 119:1992;1017-1921.
54. Stratford-Perricaudet L.D., Makeh I., Perricaudet M., Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90:1992;626-630.
55. Sundström E., Fredriksson A., Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice a model for Parkinson's disease . Brain Res. 528:1990;181-188.
56. Tomac A., Lindqvist E., Lin L.F.H., Ögren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 373:1995;335-339.
57. Unsicker K., Flanders K.C., Cissel D.S., Lafyatis R., Sporn M.B. Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neurosci. 44:1991;613-625.
58. Van der Wal E.A., Gómez-Pinilla F., Cotman C.W. Transforming growth factor β1 is in plaques in Alzheimer and Down pathologies. NeuroReport. 4:1993;69-72.
59. Vawter M.P., Dillon-Carter O., Tourtellote W.W., Carvey P., Freed W.J. TGF beta 1 and TGF beta 2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142:1996;313-322.
60. Wakefield L.M., Smith M.B., Broz S., Jackson M., Levinson A.D., Sporn M.B. Recombinant TGFβ1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGFβ1 complex. Growth Factors. 1:1989;203-218.
61. Wyss-Coray T., Lin C., Sanan D., Mucke L., Masliah E. Chronic overproduction of TGF-β1 in astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am. J. Pathol. 156:2000;139-150.
62. Wyss-Coray T., Lin C., Yang F., Yu G., Rhode M., McConlogue L., Masliah E., Mucke L. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7:2001;612-618.
63. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., Mucke L. Amyloidogenic role of cytokine TGFβ1 in transgenic mice and in Alzheimer's disease. Nature. 389:1997;603-606.
64. Young W.S., Bonner T.I., Braun M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
65. Yu C., Takeda M., Soliven B. Regulation of cell cycle proteins by TNF-alpha and TGF-beta in cells of oligodendroglial lineage. J. Neuroimmunol. 108:2000;2-10.
66. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons some clinical and basic implications . Trend Neurosci. 13:1990;290-296.